The purpose of this study is to assess the impact of treatment of anemia with darbepoetin alfa on mortality and cardiovascular morbidity in patients with chronic kidney disease and type 2 diabetes.

Official Title


Kidney Disease, Nephritis, Diabetes Mellitus, anaemia

Study Type


Study Design


Further Details

Primary Outcome Measures:

  • Mortality
  • Cardiovascular morbidity (TIA, MI, CHF, CVA, myocardial ischemia)

Secondary Outcome Measures:

  • Time to all-cause mortality
  • Time to cardiovascular mortality
  • Time to MI
  • Time to CVA
  • Time to CHF
  • Time to ESRD
  • Rate of decline in eGFR relative to baseline
  • Change in patient reported fatigue relative to baseline at week 25

Study Start

Eligibility & Criteria

  • Ages Eligible for Study: 18 Years and above
  • Genders Eligible for Study: Both

Inclusion Criteria:

  • Hemoglobin less than or equal to 11 g/dL
  • History of Chronic Kidney Disease
  • eGFR greater than or equal to 20 mL/min and less than or equal to 60 mL/min
  • Tsat greater than 15%

Exclusion Criteria:

  • Uncontrolled hypertension
  • Erythropoietic protein use within 12 weeks of randomization
  • Total Enrolment

    Contact Details

    More information available from AmgenTrials

    • Research Site, Nedlands, Western Australia, Australia; Recruiting
    • Research Site, Woodville, South Australia, Australia; Recruiting

    Published report results

    All content and media on the HealthEngine Blog is created and published online for informational purposes only. It is not intended to be a substitute for professional medical advice and should not be relied on as health or personal advice. Always seek the guidance of your doctor or other qualified health professional with any questions you may have regarding your health or a medical condition. Never disregard the advice of a medical professional, or delay in seeking it because of something you have read on this Website. If you think you may have a medical emergency, call your doctor, go to the nearest hospital emergency department, or call the emergency services immediately.